Publication

Publication (논문)

대표 논문

• Won W, Lee EH, Gotina L, Chun H, Lee JH, Bhalla M, Park U, Kim D, Kim TY, Choi JW, Kim Y, Park SJ, Lim J, Park JH, Kim HJ, Heo JY, Chung W, Oh MJ, An HJ, Lee J, Oh SJ, Ryu H, Pae AN, Park KD*, Lee CJ*. Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases. Signal Transduct. Target Ther. 2025 10(1):270 

• Kim Y, Kim J, Kim B, Kim R, Kim HJ, Lee EH, Kim J, Park J, Jeong Y, Park SI, Kim H, Kang M, Lee J, Bahn YS*, Choi JW*, Park JH*, Park KD*. Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis. J. Med. Chem. 2024 67(19):17866-17892 .

• Kim HJ, Kim H, Song J, Hong JY, Lee EH, Londhe AM, Choi JW, Park SJ, Oh E, Yoon H, Hwang H, Hahn D, Jung K, Kwon S, Kadayat TM, Ma MJ, Joo J, Kim J, Bae JH, Hwang H, Pae AN, Cho SJ, Park JH*, Chin J*, Kang H*, Park KD*. Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease. Theranostics 2024 14(16):6088-6108.

• Cha E, Kim J, Gotina L, Kim J, Kim HJ, Seo SH, Park JE, Joo J, Kang M, Lee J, Hwang H, Kim HJ, Pae AN*, Park KD*, Park JH*, Lim SM*. Exploration of Tetrahydroisoquinoline- and Benzo[c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis J. Med. Chem. 2023 66(15):10381-10412. 

• Park S. J., Yeon S. K., Kim Y., Kim H. J., Kim S., Kim J., Choi J. W., Kim B., Lee E. H., Kim R., Seo S. H., Lee J., Kim J. W., Lee H. Y., Hwang H., Bahn Y. S., Cheong E., Park J. H.*, Park K. D.* Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis. J. Med. Chem. 2022. 65(4), 3539-3562. (Cover article)

• Choi J. W., Lee K. T., Kim S., Lee Y. R., Kim H. J., Seo K. J., Lee M. H., Yeon S. K., Jang B. K., Park S. J., Kim H. J., Park J.-H., Kim D., Lee D. G., Cheong E., Lee J. S.*, Bahn Y. S.*, Park K. D.* Optimization and evaluation of novel antifungal agents for the treatment of fungal infection. J. Med. Chem. 2021, 64, 15912-15935. (Cover article)

• Park J.-H., Ju Y. H., Choi J. W., Song H. J., Jang B. K., Woo J. Chun H., Kim H. J., Shin S. J., Yarishkin O., Jo S., Park M., Yeon S. K., Kim S. Kim J., Nam M.-H., Londhe A. M., Kim J., Cho S. J., Cho S. M., Lee C., Hwang S. Y., Kim S. W., Oh S.-J., Cho J., Pae A. N., Lee C. J.*, Park K. D.* Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Science Advances. 2019, 5(3), eaav0316.

• Choi J. W., Kim S., Park J.-H., Kim H. J., Shin S. J., Kim J. W., Woo S. Y., Lee C., Han S. M., Lee J., Pae A. N., Han G., Park K. D.* Optimization of vinyl sulfone derivatives as potent nuclear factor erythroid 2-related factor 2 (Nrf2) activators for Parkinson’s disease therapy. Journal of Medicinal Chemistry. 2019, 62, 811-830.

• Lee J. A., Kim J. H., Woo S. Y., Son H. J., Han S. H., Jang B. K., Choi J. W., Kim D. J., Park K. D.* Hwang O.* A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia. British Journal of Pharmacology. 2015, 172(4), 1087-1100. [co-corresponding authors]

• Woo S. Y, Kim J. H., Moon M. K., Han S.-H., Yeon S. K., Choi J. W., Jang B. K., Song H. J., Kang Y. G., Kim J. W., Lee J., Kim D. J., Hwang O. Y.,* Park K. D.* Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson’s disease therapy. Journal of Medicinal Chemistry. 2014, 57 (4), 1473-1487.

KIST & KIST School, UST (2011~ )

1. Won W, Lee EH, Gotina L, Chun H, Lee JH, Bhalla M, Park U, Kim D, Kim TY, Choi JW, Kim Y, Park SJ, Lim J, Park JH, Kim HJ, Heo JY, Chung W, Oh MJ, An HJ, Lee J, Oh SJ, Ryu H, Pae AN, Park KD*, Lee CJ*. Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases. Signal Transduct. Target Ther. 2025 10(1):270

2.  Lee CY, Gotina L, Kim J, Kim J, Ahn JY, Son WS, Seo SH, Park J, Kang M, Lee J, Lee JY, Park KD, Lim SM, Park JH, Pae AN. Discovery of Novel β-Arrestin Biased Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis. J. Med. Chem. 2025 doi: 10.1021/acs.jmedchem.5c00859

3. Yoon S, Won W, Lee S, Han K, Ha E, Lee J, Hyeon SJ, Joo Y, Hong H, Lee H, Song Y, Park KD, Huber BR, Lee J, Edden RAE, Suh M, Ryu H, Lee CJ, Lyoo IK. Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder. Signal Transduct. Target Ther. 2025 10(1):240

4. Jiang YP, Wen JJ, Ma X, Yuan CR, Zhou F, Zheng MJ, Tang X, Yu XK, Lai WD, Zhou YH, Yu WH, You WT, Jin Y, Park KD, Khanna R, Wen CP, Yu J. CRMP2 phosphorylation regulates polarization and spinal infiltration of CD4 + T lymphocytes, inhibits spinal glial activation, and arthritic pain. Pain 2025 166(9): 2162-2180.

5.  Kim Y, Kim J, Kim B, Kim R, Kim HJ, Lee EH, Kim J, Park J, Jeong Y, Park SI, Kim H, Kang M, Lee J, Bahn YS*, Choi JW*, Park JH*, Park KD*. Discovery and Optimization of a Series of Vinyl Sulfoximine-Based Analogues as Potent Nrf2 Activators for the Treatment of Multiple Sclerosis. J. Med. Chem. 2024 67(19):17866-17892 .

6. Kim HJ, Kim H, Song J, Hong JY, Lee EH, Londhe AM, Choi JW, Park SJ, Oh E, Yoon H, Hwang H, Hahn D, Jung K, Kwon S, Kadayat TM, Ma MJ, Joo J, Kim J, Bae JH, Hwang H, Pae AN, Cho SJ, Park JH*, Chin J*, Kang H*, Park KD*. Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease. Theranostics 2024 14(16):6088-6108.

7. Ju YH, Cho J, Park JY, Kim H, Hong EB, Park KD, Lee CJ, Chung E, Kim HI, Nam MH. Tonic excitation by astrocytic GABA causes neuropathic pain by augmenting neuronal activity and glucose metabolism.  Exp. Mol. Med. 2024 56(5):1193-1205

8. Kim J, Choi JW, Kim HJ, Kim B, Kim Y, Lee EH, Kim R, Kim J, Park J, Jeong Y, Park JH, Park KD*. Phloroglucinol Derivatives Exert Anti-inflammatory Effects and Attenuate Cognitive Impairment in LPS-induced Mouse Model. ChemMedChem 2024 16:e202400056.

9.  Won D, Lee EH, Chang JE, Nam MH, Park KD, Oh SJ, Hwang JY. The role of astrocytic γ-aminobutyric acid in the action of inhalational anesthetics. Eur. J. Pharmacol. 2024 970:176494

10.  Kim D, Ko HY, Chung JI, Park YM, Lee S, Kim SY, Kim J, Chun JH, Han KS, Lee M, Ju YH, Park SJ, Park KD, Nam MH, Kim SH, Shim JK, Park Y, Lim H, Park J, Lee GH, Kim H, Kim S, Park U, Ryu H, Lee SY, Park S, Kang SG, Chang JH, Lee CJ, Yun M. Visualizing cancer-originating acetate uptake through monocarboxylate transporter 1 in reactive astrocytes in the glioblastoma tumor microenvironment. Neuro Oncol. 2024 26(5):843-857

11.  Chae U, Chun H, Lim J, Shin H, Smith WC, Choi JW, Park KD, Lee CJ, Cho IJ. KDS2010, a reversible MAO-B inhibitor, extends the lifetime of neural probes by preventing glial scar formation. Glia 2024 72(4):748-758

12. Cha E, Kim J, Gotina L, Kim J, Kim HJ, Seo SH, Park JE, Joo J, Kang M, Lee J, Hwang H, Kim HJ, Pae AN*, Park KD*, Park JH*, Lim SM*. Exploration of Tetrahydroisoquinoline- and Benzo[c]azepine-Based Sphingosine 1-Phosphate Receptor 1 Agonists for the Treatment of Multiple Sclerosis J. Med. Chem. 2023 66(15):10381-10412.

13.  Sa M, Yoo ES, Koh W, Park MG, Jang HJ, Yang YR, Bhalla M, Lee JH, Lim J, Won W, Kwon J, Kwon JH, Seong Y, Kim B, An H, Lee SE, Park KD, Suh PG, Sohn JW, Lee CJ. Hypothalamic GABRA5-positive neurons control obesity via astrocytic GABA. Nat. Metab. 2023 5(9):1506-1525.

14. Hassan AHE, Kim HJ, Park K, Choi Y, Moon S, Lee CH, Kim YJ, Cho SB, Gee MS, Lee D, Park JH, Lee JK, Ryu JH, Park KD, Lee YS. Synthesis and Biological Evaluation of O6-Aminoalkyl-Hispidol Analogs as Multifunctional Monoamine Oxidase-B Inhibitors towards Management of Neurodegenerative Diseases. Antioxidants 2023 12(5):1033.

15. Kim KT, Cho DW, Cho JW, Im WJ, Kim DH, Park JH, Park KD, Yang YS, Han SC. Two weeks dose range-finding and four weeks repeated dose oral toxicity study of a novel reversible monoamine oxidase B inhibitor KDS2010 in cynomolgus monkeys. Toxicol. Res. 2023 39(4):693-709.

16. Kim B, Kim R, Kim HJ, Kim Y, Park SJ, Lee EH, Kim J, Kim J, Choi JW, Park JH, Park KD. Optimization and evaluation of pyridinyl vinyl sulfones as Nrf2 activator for the antioxidant and anti-inflammatory effects. Eur. J. Med. Chem. 2023, 256, 115433.

17. Nam MH, Ko HY, Kim D, Lee S, Park YM, Hyeon SJ, Won W, Chung JI, Kim SY, Jo HH, Oh KT, Han YE, Lee GH, Ju YH, Lee H, Kim H, Heo J, Bhalla M, Kim KJ, Kwon J, Stein TD, Kong M, Lee H, Lee SE, Oh SJ, Chun JH, Park MA, Park KD, Ryu H, Yun M, Lee CJ. Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG. Brain 2023 awad037

18. Joo Y, Sung JY, Shin SM, Park SJ, Kim KS, Park KD, Kim SB, Lee DW. A Retro-Aldol Reaction Prompted the Evolvability of a Phosphotransferase System for the Utilization of a Rare Sugar. Microbiol Spectr. 2023 e0366022

19. Phạm TL, Noh C, Neupane C, Sharma R, Shin HJ, Park KD, Lee CJ, Kim HW, Lee SY, Park JB. MAO-B Inhibitor, KDS2010, Alleviates Spinal Nerve Ligation-induced Neuropathic Pain in Rats Through Competitively Blocking the BDNF/TrkB/NR2B Signaling. J Pain 2022 23(12), 2092-2109 

20. Jiang YP, Wang S, Lai WD, Wu XQ, Jin Y, Xu ZH, Moutal A, Khanna R, Park KD, Shan ZM, Wen CP, Yu J. Neuronal CRMP2 phosphorylation inhibition by the flavonoid, naringenin, contributes to the reversal of spinal sensitization and arthritic pain improvement. Arthritis Res. Ther. 2022 24(1), 277

21. Park SJ, Kim J, Kim J, Kim Y, Lee EH, Kim HJ, Kim S, Kim B, Kim R, Choi JW, Park J-H, Park KD. Synthesis and Evaluation of Serinolamide Derivatives as Sphingosine-1-Phosphate-1 (S1P1) Receptor Agonists. Molecules 2022 27(9), 2818.

22. Park SE, Neupane C, Noh C, Sharma R, Shin HJ, Pham TL, Lee GS, Park KD, Lee CJ, Kang DW, Lee SY, Kim HW, Park JB. Antiallodynic effects of KDS2010, a novel MAO-B inhibitor, via ROS-GABA inhibitory transmission in a paclitaxel-induced tactile hypersensitivity model. Mol. Brain 2022 15, 41 

23. Jung YH, Kim YO, Kang KM, Lee HG, Son B, Han X, Oh E, Kim S, Seo SH, Park JH, Park KD, Kim WM, Yoon MH, Kim YC. Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain. Pharmaceuticals 2022 15(4), 407.

24. Hassan AHE, Kim HJ, Gee MS, Park JH, Jeon HR, Lee CJ, Choi Y, Moon S, Lee D, Lee JK, Park KD, Lee YS. Positional scanning of natural product hispidol's ring-B: discovery of highly selective human monoamine oxidase-B inhibitor analogues downregulating neuroinflammation for management of neurodegenerative diseases. J Enzyme Inhib Med Chem. 2022 37(1), 768-780

25. Lee KT, Lee DG, Choi JW, Park JH, Park KD, Lee JS, Bahn YS. The novel antifungal agent AB-22 displays in vitro activity against hyphal growth and biofilm formation in Candida albicans and potency for treating systemic candidiasis. J Microbiol. 2022 60(4), 438-443.

26.  Lee J, Kim JG, Hong S, Kim YS, Ahn S, Kim R, Chun H, Park KD, Jeong Y, Kim DE, Lee CJ, Ku T, Kim P. Longitudinal intravital imaging of cerebral microinfarction reveals a dynamic astrocyte reaction leading to glial scar formation. Glia 2022, 70(2), 975-988.

27. Park S. J., Yeon S. K., Kim Y., Kim H. J., Kim S., Kim J., Choi J. W., Kim B., Lee E. H., Kim R., Seo S. H., Lee J., Kim J. W., Lee H. Y., Hwang H., Bahn Y. S., Cheong E., Park J. H.*, Park K. D.*  Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.  J. Med. Chem. 2022. 65(4), 3539-3562. (Cover article)

28. Chun H., Lim J., Park K. D., Lee C. J. Inhibition of monoamine oxidase B prevents reactive astrogliosis and scar formation in stab wound injury model. Glia 2022, 70(2), 354-367. 

29. Choi J. W., Lee K. T., Kim S., Lee Y. R., Kim H. J., Seo K. J., Lee M. H., Yeon S. K., Jang B. K., Park S. J., Kim H. J., Park J.-H., Kim D., Lee D. G., Cheong E., Lee J. S.*, Bahn Y. S.*, Park K. D.* Optimization and evaluation of novel antifungal agents for the treatment of fungal infection. J. Med. Chem. 2021, 64, 15912-15935. (Cover article)

30. Elsherbeny M. H., Kim J., Gouda N. A., Gotina L., Cho J., Pae A. N., Lee K., Park K. D., Elkamhawy A., Roh E. J. Highly potent, selective, and competitive indole-based MAO-B inhibitors protect PC12 cells against 6-hydroxydopamine- and rotenone-induced oxidative stress. Antioxidants 2021, 10(10):1641.

31. Elkamhawy A., Woo J., Gouda N. A. Kim J., Nada H, Roh E. J., Park K. D.*, Cho J.*, Lee K.* Melatonin analogues potently inhibit MAO-B and protect PC12 cells against oxidative stress. Antioxidants 2021, 10(10):1604.

32. Nam M.-H., Park J.-H., Song H.-J., Choi J. W., Kim S., Jang B. K., Yoon H. H., Heo J. Y., Lee H., An H., Kim H. J., Park S. J., Cho D.-W., Yang Y.-S., Han S.-C., Kim S., Oh S.-J., Jeon S. R., Park K. D.*, Lee C. J.* KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson’s disease. Neurotherapeutics 2021, 18, 1729-1747.

33. Elkamhawy A., Paik S., Park J.-H., Kim H. J., Hassan A. H. E., Lee K., Park K. D.* Rho E. J.* Discovery of novel and potent safinamide-based derivatives as highly selective hMAO-B inhibitors for treatment of Parkinson’s disease (PD): Design, synthesis, in vitro, in vivo and in silico biological studies. Bioorganic Chemistry 2021, 115, 105233

34. Kim S. K.*, Park K. D.*, Lee D. W.* Editorial: Interactions between small molecule ligands and target enzymes. Front Mol. Biosci. 2021, 5;8:649450.

35. Choi J. W., Kim S., Yoo J. S., Kim H. J., Kim H. J., Kim B. E., Lee E. H., Lee Y. S., Park J. H.*, Park K. D.* Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease. Eur. J. Med. Chem. 2021, 212, 113103.

36. Chun H., Im H., Kang Y. J., Kim Y., Shin J. H., Won W., Lim J., Ju Y., Park Y. M., Kim S., Lee S. E., Lee J., Woo J., Hwang Y., Cho H., Jo S., Park J. H., Kim D., Kim D. Y., Seo J. S., Gwag B. J., Kim Y. S., Park K. D., Kaang B. K., Cho H., Ryu H., Lee C. J. Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2 production. Nat. Neurosci. 2020, 23(12), 1555-1566.

37. Choi J. W., Kim G. J., Kim H. J., Nam J.-W., Kim J., Chin J., Park J.-H., Choi H., Park K.D.* Identification and evaluation of a napyradiomycin as a potent Nrf2 activator: antioxidative and anti-inflammatory activities. Bioorganic Chemistry 2020, 105, 104434

38. Kwak H., Koh W., Kim S., Song K., Shin J. I., Lee J. M., Lee E. H., Bae J. Y., Ha G. E., Oh J. E., Park Y. M., Kim S., Feng J., Lee S. E., Choi J. W., Kim K. H., Kim Y. S., Woo J., Lee D., Son T., Kwon S. W., Park K. D., Yoon B. E., Lee J., Li Y., Lee H., Bae Y. C., Lee C. J., Cheong E. Astrocytes Control Sensory Acuity via Tonic Inhibition in the Thalamus. Neuron 2020, 108, 691-706

39. Kim K. T., Kim D. H., Kim B. K., Han J. S., Eom H. Y., Yang M. J., Shin S. H., Cho D. W., Jang B. K., Park K. D., Yang Y. S., Han S. C. Four-week repeated dose oral toxicity study of KDS2010, a novel selective monoamine oxidase B inhibitor, in Sprague Dawley rats. Regul. Toxicol. Pharmacol. 2020, 117, 104773.

40. Elkamhawy A., Paik S., Kim H. J., Park J. H., Londhe A. M., Lee K., Pae A. N., Park K. D., Roh E. J. Discovery of N-(1-(3-fluorobenzoyl)-1 H-indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B. J. Enzyme Inhib. Med. Chem. 2020, 35(1), 1568-1580.

41. Nam M. H., Cho J., Kwon D. H., Park J. Y., Woo J., Lee J. M., Lee S., Ko H. Y., Won W., Kim R. G., Song H., Oh S. J., Choi J. W., Park K. D., Park E. K., Jung H., Kim H. S., Lee M. C., Yun M., Lee C. J., Kim H. I. Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes Functional Recovery after Subcortical Stroke. Cell Rep. 2020, 32, 107861

42. Choi J. W., Ju Y. H., Choi Y., Hyeon S. J., Gadhe C. G., Park J. H., Kim M. S., Baek S., Kim Y., Park K. D., Pae A. N., Ryu H., Lee C. J., Cho B. R. PyrPeg, a Blood-Brain-Barrier-Penetrating Two-Photon Imaging Probe, Selectively Detects Neuritic Plaques, Not Tau Aggregates. ACS Chem. Neurosci. 2020,

43. Hassan A. H. E., Park K. T., Kim H. J., Lee H. J., Kwon Y. H., Hwang J. Y., Jang C. G., Chung J. H., Park K. D., Lee S. J., Oh S. J., Lee Y. S. Fluorinated CRA13 Analogues: Synthesis, in Vitro Evaluation, Radiosynthesis, in Silico and in Vivo PET Study. Bioorg Chem. 2020, 99:103834.

44. Kim S., Viswanath A. N. I., Park J.-H., Lee H. E., Park A. Y., Choi J. W., Kim H. J., Londhe A. M., Jang B. K., Lee J., Hwang H., Lim S. M., Pae A. N.*, Park K. D.* Nrf2 activator via interference of Nrf2-Keap1 interaction has antioxidant and anti-inflammatory properties in Parkinson’s disease animal model. Neuropharmacology. 2020, 167, 107989

45. Heo J. Y., Nam M. H., Yoon H. H., Kim J., Hwang Y. J., Won W., Woo D. H., Lee J. A., Park H. J., Jo S., Lee M. J., Kim S., Shim J. E., Jang D. P., Kim K. I., Huh S. H. , Jeong J. Y., Kowall N. W., Lee J., Im H., Park J. H., Jang B. K., Park K. D., Lee H. J., Shin H., Cho I. J., Hwang E. M., Kim Y., Kim H. Y., Oh S. J., Lee S. E., Paek S. H., Yoon J. H., Jin B. K., Kweon G. R., Shim I., Hwang O., Ryu H., Jeon S. R., Lee C. J. Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease. Curr. Biol. 2020, 30(2), 276-291.

46. Farag A. K., Hassan A. H. E., Ahn B. S., Park K. D., Roh E. J. Reprofiling of pyrimidine-based DAPK1/CSF1R dual inhibitors: identification of 2,5-diamino-4-pyrimidinol derivatives as novel potential anticancer lead compounds. J. Enzyme Inhib. Med. Chem. 2020, 35(1), 311-324.

47. Kim H. J., Jang B. K., Park J.-H., Choi J. W., Park S. J., Byeon S. R., Pae A. N., Lee Y. S., Cheong E., Park K. D.* A novel chalcone derivative as Nrf2 activator attenuates learning and memory impairment in a scopolamine-induced mouse model. European Journal of Medicinal Chemistry. 2020, 185, 1117

48. Choi J. W., Shin S. J., Kim H. J., Park J.-H., Kim H. J., Lee E. H., Pae A. N., Bahn Y. S., Park K. D.* Antioxidant, anti-inflammatory, and neuroprotective effects of novel vinyl sulfonate compounds as Nrf2 activator. ACS Medicinal Chemistry Letters. 2019, 10(7), 1061-1067 (cover article)

49. Jeong P., Kim S.-K., Li Q., Oh S.-J., Son S., Chen G., Tan H., Kim S., Park J.-H., Park K. D., Kim Y. O., Yoon M. H., Kim Y.-C., Goddard W. A. Discovery of Novel Biased Opioid Receptor Ligands through Structure-Based Pharmacophore Virtual Screening and Experiment. ChemMedChem. 2019, 14, 1783-1794

50. Nam M.-H., Han K.-S., Lee J., Won W., Koh W., Bae J. Y., Woo J., Kim J., Kwong E., Choi T.-Y., Chun H., Lee S. E., Kim S.-B., Park K. D., Choi S.-Y., Bae Y. C., Lee C. J. Activation of Astrocytic mu-opioid receptor causes conditioned place preference. Cell Reports. 2019, 28, 1154-1166.

51. Khanna R., Yu J., Yang X., Moutal A., Chefdeville A., Gokhale V., Shuja Z., Chew L. A., Hellampalli S. S., Luo S., Francois-Moutal L., Serafini M. J., Ha T., Perez-Miller S., Park K. D., Patwardhan A. M., Streicher J. M., Colecraft H. M., Khanna M. Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Pain. 2019, 160, 1644-1661

52. Hamida S. B., Laguesse S., Morisot N., Park J.-H., Phuamluong K., Berger A. L., Park K. D., Ron D. Mammalian target of rapamycin complex I and its downstream effector collapsing response mediator protein-2 drive reinstatement of alcohol reward seeking. Addiction Biology, 2019, 24(5), 908-920

53. Yu J., Moutal A., Dorame A., Bellampalli S. S., Chefdeville A., Kanazawa I., Pham N. Y. N., Park K. D., Weimer J. M., Khanna R. Phosphorylated CRMP2 regulates spinal nociceptive neurotransmission. Molecular Neurobiology. 2019, 56, 5241-5255.

54. White K. A., Cain J. T., Magge H., Yeon S. K., Park K. D. Khanna R., Weimer J. M. Modulation of CRMP2 via (S)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease. Neuronal Signaling. 2019, 3, NS20190001

55. Park J.-H., Ju Y. H., Choi J. W., Song H. J., Jang B. K., Woo J. Chun H., Kim H. J., Shin S. J., Yarishkin O., Jo S., Park M., Yeon S. K., Kim S. Kim J., Nam M.-H., Londhe A. M., Kim J., Cho S. J., Cho S. M., Lee C., Hwang S. Y., Kim S. W., Oh S.-J., Cho J., Pae A. N., Lee C. J.*, Park K. D.* Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Science Advances. 2019, 5(3), eaav0316.

56. Choi J. W., Kim S., Park J.-H., Kim H. J., Shin S. J., Kim J. W., Woo S. Y., Lee C., Han S. M., Lee J., Pae A. N., Han G., Park K. D.* Optimization of vinyl sulfone derivatives as potent nuclear factor erythroid 2-related factor 2 (Nrf2) activators for Parkinson’s disease therapy. Journal of Medicinal Chemistry. 2019, 62, 811-830.

57. Farag A. K., Hassan A. H. E., Jeong H., Kwon Y., Choi J. G., Oh M. S., Park K. D., Kim Y. K., Roh E. J. First-in-class DAPK1/CSF1R dual inhibitors: Discovery of 3,5-dimethoxy-N-(4-(4-methoxyphenoxy)-2-((6-morpholinopyridin-3-yl)amino)pyrimidin-5-yl)benzamide as a potential anti-tauopathies agent. European Journal of Medicinal Chemistry. 2019, 162, 161-175.

58. Lee J. A., Kim H. R., Kim J., Park K. D., Kim D. J., Hwang O. The Novel Neuroprotective Compound KMS99220 Has an Early Anti-neuroinflammatory Effect via AMPK and HO-1, Independent of Nrf2. Experimental Neurobiology. 2018, 27, 408-418.

59. Hassana A. H. E., Cho M. C., Kim H. I., Yang J. S., Park K. T., Hwang J. Y., Jang C.-G., Park K. D., Lee Y. S. Synthesis of oxidative metabolites of CRA13 and their analogs: Identification of CRA13 active metabolites and analogs thereof with selective CB2R affinity. Bioorganic & Medicinal Chemistry. 2018, 26, 5069-5078.

60. Lee J. A., Son H. J., Choi J. W., Kim J., Han S. H., Shin N., Kim J. H., Kim S. J., Heo J. Y., Kim D. J., Park K. D.,* Hwang O.* Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220. Neurochemistry International. 2018, 112, 96-107.

61. Yeon S. K., Choi J. W., Park J.-H., Lee Y. R., Kim H. J., Shin S. J., Jang B. K., Kim S., Bahn Y. S., Han G., Lee Y. S., Pae A. N., Park K. D.* Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B Inhibitors toward Parkinson’s disease therapy. Bioorganic & Medicinal Chemistry. 2018, 26, 232-244.

62. Moutal A., Villa L. S., Yeon S. K., Householder K. T., Park K. D., Sirianni R. W., Khanna R. CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation. Molecular Neurobiology. 2018, 55, 4403-4416.

63. Moutal A., Yang X., Li W., Gilbraith K. B., Luo S., Cai S., François-Moutal L., Chew L. A., Yeon S. K., Bellampalli S. S., Qu C., Xie J. Y., Ibrahim M. M., Khanna M., Park K. D., Porreca F., Khanna R. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1 (NF1)-related pain that is reversed by (S)-Lacosamide. Pain. 2017, 158(12), 2301-2319.

64. Kim T,, Son W. S., Morshed M. N., Londhe A. M., Jung S. Y., Park J. H., Park W. K., Lim S. M., Park K. D., Cho S. J., Jeong K. S., Lee J, Pae A. N. Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity. European Journal of Medicinal Chemistry. 2017, 141, 240-256.

65. Nam M. H, Park M., Park H., Kim Y., Yoon S., Sawant V. S., Choi J. W., Park J. H., Park K. D., Min S. J., Lee C. J., Choo H. Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease. ACS Chemical Neuroscience. 2017, 8, 1519-1529.

66. Kang T. H., Lee Y. M., Lee W. J., Hwang E. I., Park K. D., Choi G. J., Moon J. S., Park H. Y., Kim S. U. Antifungal Activities of Dimeric Sesquiterpenes, Shizukaols C and F, Isolated from Chloranthus japonicus Sieb. Journal of Microbiology and Biotechnology. 2017, 27, 1272-1275.

67. Elkamhawy A., Park J. E., Hassan A. H. E., Pae A. N., Lee J., Park B. G., Paik S., Do J., Park J. H., Park K. D., Moon B., Park W. K., Cho H., Jeong D. Y., Roh E. J. Design, synthesis, biological evaluation and molecular modelling of 2-(2-aryloxyphenyl)-1,4-dihydroisoquinolin-3(2H)-ones: A novel class of TSPO ligands modulating amyloid-β-induced mPTP opening. European Journal of Pharmaceutical Science. 2017, 104, 366-381.

68. Kim T., Yang H. Y., Park B. G., Jung S. Y., Park J.-H., Park K. D., Min S.-J., Tae J., Yang H., Cho S., Cho S. J., Song H., Mook-Jung I., Lee J., Pae A. N. Discovery of benzimidazole derivatives as odulators of mitochondrial function: A potential treatment for Alzheimer's disease. European Journal of Medicinal Chemistry. 2017, 125, 1172-1192.

69. Cha E., Lee K. M., Park K. D., Park K. S., Lee K.-W., Kim S. M., Lee J. Hydroxycholesterol levels in the serum and cerebrospinal fluid of patients with neuromyelitis optica revealed by LC-Ag+CIS/MS/MS and LC-ESI/MS/MS with picolinic derivatization: Increased levels and association with disablility during acute attack. PLoS ONE 2016, 11(12); e0167819. doi:10.1371/journal.pone.0167819 (12/12/2016)

70. Moutal A., Eyde N., Telemi E., Park K. D., Xie J. Y., Dodick D. W., Porreca F., Khanna R. Efficacy of (S)-lacosamide in preclinical models of cephalic pain. Pain Reports 2016, 1, e565

71. Lee J. A., Son H. J., Kim J. H., Park K. D., Shin N., Kim H. R., Kim E. M., Kim D. J. Hwang O. A novel synthetic isothiocyanate ITC-57 displays antioxidant, anti-inflammatory, and neuroprotective properties in a mouse Parkinson’s disease model. Free Radical Research 2016, 50, 1188-1199.

72. Yang H., Woo J., Pae A. N., Um M. Y., Cho N. C., Park K. D., Yoon M. S., Kim J., Lee C. J., Cho S. α-Pinene, a Major Constituent of Pine Tree Oils, Enhances Non-Rapid Eye Movement Sleep in Mice through GABAA-benzodiazepine Receptors. Molecular Pharmacology 2016. 90, 530-539.

73. Kim J. S., Cheon S., Kim S. W., Kim B., Kim H., Park K. D.,* Kim S. M.,* Glycyrrhizic acid prevents astrocyte death by neuromyelitis optica-specific IgG via inhibition of C1q binding. Biochem. Biophys. Res. Commun. 2016. 478, 553-558. (09/16/2016) [co-corresponding authors]

74. Viswanath A. N., Jung S. Y., Hwang E. M., Park K. D., Lim S. M., Min S. J., Cho Y. S., Pae A. N., Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently. Chemical Biology & Drug Design. 2016. 88, 807-819 (12/2016)

75. Moutal A., Chew L. A., Yang X., Wang Y., Yeon S. K., Telemi E., Meroueh S., Park K. D., Shrinivasan R., Gilbraith K. B., Qu C., Xie J. Y., Patwardhan A., Vanderah T. W., Khanna M., Porreca F., Khanna R. (S)- Lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain. 2016, 157, 1448-1463. (07/01/2016)

76. Moutal A., Francois-Moutal L., Perez-Miller S., Cottier K., Cew L. A., Yeon S. K., Dai J., Park K. D., Khanna M., Khanna R. (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Molecular Neurobiology. 2016, 53 (3), 1959-1976

77. Ju E. J., Yeon S. K., Park J.-H., Cheon S. Y., Choi J. W., Ha T., Jang B. K., Kim S., Kang Y. G., Hwang H., Cho S. J., Cheong E., Bahn Y., Pae A. N., Kim S. M., Park K. D.* Screening, synthesis, and in Vitro evaluation of vinyl sulfones as inhibitors of complement-dependent cytotoxicity in neuromyelitis optica. ChemMedChem. 2016, 11, 377-381.(cover article)

78. Cha E., Kim S., Lee K. M., Kim H. J., Kim K. H., Kwon O.-S., Park K. D., Lee J. Relationship between chromatographic resolution and amide structure of chiral 2-hydroxy acids ans O-(-)-menthoxycarbonylated diastereomeric derivatives for enantiomeric separation on achiral gas chromatography. Journal of Chromatography B. 2016, 1012, 17-22.

79. Jang J. W., Cho N.-C., Min S.-J., Cho Y. S., Park K. D., Seo S. H., No K. T., Pae A. N. Novel scaffold identification of mGlu1 receptor negative allosteric modulators using a hierarchical virtual screening approach. Chemical Biology & Drug Design. 2016. 87, 239-256. (02/01/2016)

80. Nam V. H., Kim J. Y., Hassan A.H. E., Choi K., Park J.-H., Park K. D., Lee J. K., Pae A. N., Choo H., Min S.-J., Cho Y. S. Synthesis and biological evaluation of picolinamides and thiazole-2-carboxamides as mGluR5 (metabotropic glutamate receptor 5) antagonists. Bioorganic & Medicinal Chemistry Letters. 2016, 26, 140-144. (01/01/2016)

81. Cho N.-C., Cha J. H., Kim H., Kwak J., Kim D., Seo S.-H., Shin J.-S., Kim T., Park K. D., Lee J., No K. T., Kim Y. K., Lee K.-T., Pae A. N., Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists. Bioorganic & Medicinal Chemistry. 2015, 23, 7717-7727. (12/15/2015)

82. Park J.-H., Choi J. W., Ju E. J., Pae A. N., Park K. D.* Antioxidant and Anti-inflammatory Activities of a Natural Compound, Shizukahenriol, through Nrf2 activation. Molecules. 2015. 20, 15989-16003. (09/02/2015) 

83. Choi J. W., Jang B. K., Cho N.-C., Park J. H., Yeon S. K., Ju E. J., Lee Y. S., Han G. H., Pae A. N., Kim D. J., Park K. D.* Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorganic & Medicinal Chemistry. 2015, 19, 6486-6496. (10/01/2015) 

84. Lee J. A., Son H. J., Park K. D., Han S. H., Shin N., Kim J. H., Kim H. R., Kim D. J., Hwang O. A novel compound ITC-3 activates the Nrf2 signaling and provides neuroprotection in Parkinson’s disease model. Neurotoxicity Research. 2015

85. Kim Y., Kim M., Park M., Tae J., Baek D.-J., Park K. D., Choo H. Synthesis of Novel Dihydropyridothienopyrimidin-4,9-dione Derivatives. Molecules. 2015, 20, 5074-5084. (03/19/2015) 

86. Lee J. A., Kim J. H., Woo S. Y., Son H. J., Han S. H., Jang B. K., Choi J. W., Kim D. J., Park K. D.* Hwang O.* A novel compound VSC2 has anti-inflammatory and antioxidant properties in microglia. British Journal of Pharmacology. 2015, 172(4), 1087-1100. (02/2015). [co-corresponding authors]

87. Park K. D., Yang X. F., Dustrude E. T., Wang Y., Ripsch M. S., White F. A., Khanna R.*, Kohn H.* Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamide and safinamide. ACS Chemical Neuroscience. 2015, 6 (2), 316-330. (02/18/2015). 

88. Bang S., Kwon H., Hwang H. S., Park K. D., Kim S. U., Bahn Y. S. 9-O-butyl-13-(4-isopropylbenzyl) berberine, KR-72, Is a potent antifungal agent that inhibits the growth of Cryptococcus neoformans by regulating gene expression. PLoS ONE 2014, 9(10); e109863. Doi:10.1371/journal.pone.0109863 (10/10/2014) 

89. Lee H.╪, Park K. D.╪, Torregrosa R., Yang X.-F., Dustrude E. T., Wang Y., Wilson S. M., Barbosa C., Xiao Y., Cummins T. R., Khanna R., Kohn H. Substituted N-(Biphenyl-4’-yl)methyl (R)-2-Acetamido-3-methoxypropionamides: Potent Anticonvulsants That Affect Frequency (Use)-Dependence and Slow Inactivation of Sodium Channels. Journal of Medicinal Chemistry. 2014, 57 (14), 6165-6182. (07/24/2014). [ ╪ These author contributed equally to this study] 

90. Wilson S. M, Yeon S. K., Yang X.-F., Park K. D., Khanna R. Differencial regulation of collapsing response mediator protein 2 (CRMP2) phosphorylation by GSK3β and CDK5 following traumatic brain injury. Frontiers in Cellular Neuroscience. 2014, 8, article 135, 1-14. (05/28/2014) 

91. Woo S. Y, Kim J. H., Moon M. K., Han S.-H., Yeon S. K., Choi J. W., Jang B. K., Song H. J., Kang Y. G., Kim J. W., Lee J., Kim D. J., Hwang O. Y.,* Park K. D.* Discovery of vinyl sulfones as a novel class of neuroprotective agents toward Parkinson’s disease therapy. Journal of Medicinal Chemistry. 2014, 57 (4), 1473-1487. (02/27/2014) 

92. Park H. R., Kim J, Kim T., Jo S., Yeom M., Moon B., Choo I. H., Lee J., Lim E. J., Park K. D., Min S. J., Nam G., Keum G., Lee C. J., Choo H. Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease. Bioorganic & Medicinal Chemistry. 2013, 21 (17), 5480-5487. (09/01/2013) 

Before KIST (~2011년)

93. Lee H, Park K. D., Yang X.-F., Dustrude E. T., Wilson S. M., Khanna R., Kohn H. (Biphenyl-4-yl)methylammonium Chlorides: Potent Anticonvulsants That Modulate Na+ Currents. Journal of Medicinal Chemistry. 2013, 56 (14), 5931-5939. (07/25/2013)

94. Park K. D.╪, Yang X.-F.╪, Lee, H.╪, Dustrude E. T., Wang Y., Khanna R.,* Kohn H.* Discovery of lacosamide affinity bait agents that exhibit potent voltage-gated sodium channel blocking properties. ACS Chemical Neuroscience. 2013, 4 (3), 463-474. (03/20/2013). [ ╪ These author contributed equally to this study] 

95. Park K. D., Kim D. U., Reamtong O., Eyers C., Gaskell S. J., Liu. R.,* Kohn H.* Identification of a lacosamide binding protein using an affinity bait and chemical reporter strategy: 14-3-3 ζ. Journal of the American Chemical Society. 2011, 133 (29), 11320-11330. (07/27/2011). 

96. Wang Y., Wilson S. M., Brittain J. M., Ripsch M. S., Salome C., Park K. D., White F. A., Khanna R.*, Kohn H.* Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain. ACS Chemical Neuroscience. 2011, 2 (6), 317-332. (05/15/2011) 

97. Wang Y., Park K. D., Salome C., Wilson S. M., Stables J. P., Liu R., Khanna R., Kohn H.* Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. ACS Chemical Neuroscience. 2011, 2 (2), 90-106. (02/16/2011)

98. Park K. D., Cho S. J., Moon J. S., Kim S. U.* Synthesis and antifungal activity of a novel series of 13-(4-isopropylbenzyl)berberine derivatives. Bioorganic & Medicinal Chemistry Letters. 2010, 20 (22), 6551–6554 (11/15/2010) (IF: 2.420)

99. Wang Y., Brittain J. M., Jarecki B. W., Park K. D., Wilson S. M., Wang B., Hale R., Meroueh S. O., Cummins T. R., Khanna R.* In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation. Journal of Biological Chemistry. 2010, 285 (33), 25296-25307. (08/13/2010) 

100. Morieux P., Salome C., Park K. D., Stables J. P. Kohn H.* The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide. Journal of Medicinal Chemistry. 2010, 53 (15), 5716-5726. (08/12/2010) 

101. Park K. D., Stables J. P., Liu. R.,* Kohn H.* Proteomic searches comparing two (R)-lacosamide affinity baits: An electrophilic arylisothiocyanate and a photoactivated arylazide group. Organic & Biomolecular Chemistry, 2010, 8 (12), 2803-2813. (06/21/2010) 

102. Park K. D.,* Cho S. J.* Synthesis and antimicrobial activities of 3-O-alkyl analogues of (+)-catechin: Improvement of stability and proposed action mechanism. European Journal of Medicinal Chemistry, 2010, 45 (3), 1028-1033. (03/01/2010)

103. Salome C., Salome-Grosjeon E., Park K. D., Morieux P., Swendiman R., DeMarco E., Stables J. P., Kohn H.* Synthesis and anticonvulsant activities of (R)-N-(4’-substituted)benzyl 2-acetamido-3-methoxypropionamides. Journal of Medicinal Chemistry, 2010, 53 (3), 1288-1305. (02/11/2010) 

104. Park K. D., Morieux P., Salome C., Cotten S. W., Reamtong O., Eyers C., Gaskell S. J., Stables J. P., Liu R.,* Kohn H.* Lacosamide isothiocyanate-based agents: Novel agents to target and identify lacosamide receptors. Journal of Medicinal Chemistry 2009, 52 (21), 6897-6911. (11/12/2009) 

105. Park K. D., Liu R.,* Kohn H.* Useful tools for biomolecule isolation, detection, and identification: acylhydrazone-based cleavable linkers. Chemistry & Biology 2009, 16 (7), 763-772. (07/30/2009) 

106. Lee Y. M., Moon J. S., Yun B. S., Park. K. D., Choi G. J., Kim J. C., Lee S. H., Kim S. U.* Antifungal activity of CHE-23C, a dimeric sesquiterpene from Chloranthus henryi. Journal of Agricultural and Food Chemistry 2009, 57 (13), 5750-5755. (07/08/2009)

107. Yim N. H., Hwang E. I., Yun B. S., Park K. D., Moon J. S., Lee S. H., Sung N. D., Kim S. U.* Sesquiterpene furan compound CJ-01, a novel chitin synthase 2 inhibitor from Chloranthus japonicus SIEB. Biological & Pharmaceutical Bulletin 2008, 31(5), 1041-1044. (05/01/2008)

108. Song J. M., Park K. D., Lee K. H., Byun Y. H., Park J. H., Kim S. H. Kim J. H., Seong B. L.* Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Research 2007, 76 (2), 178-185. (11/01/2007)

109. Hwang E. I., Lee Y. M., Lee S. M., Yeo W. H., Moon J. S., Kang T. H., Park K. D., Kim S. U.* Inhibition of chitin synthase 2 and antifungal activity of lignans from the stem bark of Lindera erythrocarpa. Planta Medica 2007, 73 (7), 679-682. (05/31/2007)

110. Kang T.H., Hwang E. I., Yun B. S., Park K. D., Kwon B. M., Shin C. S., Kim S. U.* Inhibition of chitin synthases and antifungal activities by 2'-benzoyloxycinnamaldehyde from Pleuropterus ciliinervis and its derivatives. Biological & Pharmaceutical Bulletin 2007, 30(3), 598-602. (03/01/2007)

111. Park K. D., Lee J. H., Kim S. H., Kang T. H., Moon J. S. and Kim S. U.* Synthesis of berberine and berberrubine derivatives as antifungal agents. Bioorganic & Medicinal Chemistry Letters 2006; 16 (15), 3913-3916. (08/01/2006)

112. Cho S. J., Roh J. S., Sun W. S., Kim S. H., Park K. D.* N-Benzylbenzamides: A new class of potent tyrosinase inhibitors. Bioorganic & Medicinal Chemistry Letters 2006; 16 (10), 2682-2684. (05/15/2006) – Corresponding author

113. Kim Y. T., Kim S. E., Park K. D., Kang T. H., Lee Y. M., Lee S. H., Moon J. S. and Kim S. U.* Investigation of possible horizontal gene transfer from the leaf tissue of transgenic potato to soil bacteria, Journal of Microbiology and Biotechnology 2005; 15(5), 1130-1134. (10/28/2005)

114. Park K. D., Lee S. G., Kim S. U., Kim S. H., Sun W. S., Cho S. J. and Jeong D. H. Anticancer activity of 3-O-acyl and alkyl-(–)-epicatechin derivatives. Bioorganic & Medicinal Chemistry Letters 2004; 14 (20), 5189-5192. (10/18/2004)

115. Park K. D., Park Y. S., Cho S. J., Sun W. S., Kim S. H., Jung D. H. and Kim J. H.* Antimicrobial activity of 3-O-Acyl-(–)-epicatechin and 3-O-Acyl-(+)-catechin derivatives. Planta Medica 2004; 70 (3), 272-276. (03/01/2004)

116. Jeong D. H., Park K. D., Kim S. H., Kim K. R., Choi, S. W. Kim J. T., Choi K. H. Kim J. H.* Identification of Streptomyces sp. producing antibiotics against phytopathogenic fungi and its structure. Journal of Microbiology and Biotechnology 2004; 14(1), 212-215. (02/28/2004)

117. Sun W. S., Park Y. S., Yoo J., Park K. D., Kim S. H., Kim J. H. and Park H. J.* Rational design of an indolebutanoic acid derivatives as a novel aldose reductase inhibitor based on docking and 3D QSAR studies of phenethylamine derivatives. Journal of Medicinal Chemistry 2003; 46 (26), 5619-5627. (11/20/2003)